Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R, to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to a method of treatment and/or prophylaxis of diseases and conditions mediated by peroxysome proliferator-activated receptor gamma (PPAR?) in a mammal subject in need thereof, said method comprising administration to said mammal a compound of formula (I) or a pharmaceutically acceptable salt thereof in a therapeutically or prophylactically effective amount wherein in formula (I) W represents a COOH group or its bioisosters, or COO—C1-C4-alkyl group; Y represents NH or N—C1-C10-alkyl; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N S02-heteroaryl; R1 to R6 each independently represents a hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive. The compounds of formula (I) are the ligands of PPAR-gamma receptor.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1–C4-alkyl group; Y represents NH, N—C1–C10-alkyl, O, or S; Z represents NH, N—C1–C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1–C10-alkyl, N-aryl, NSO2—C1–C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1, to R6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO-C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R, to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to a method of treatment and/or prophylaxis of diseases and conditions mediated by peroxysome proliferator-activated receptor gamma (PPAR?) in a mammal subject in need thereof, said method comprising administration to said mammal a compound of formula (I) or a pharmaceutically acceptable salt thereof in a therapeutically or prophylactically effective amount wherein in formula (I) W represents a COOH group or its bioisosters, or COO—C1-C4-alkyl group; Y represents NH or N—C1-C10-alkyl; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N S02-heteroaryl; R1 to R6 each independently represents a hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive. The compounds of formula (I) are the ligands of PPAR-gamma receptor.

Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1–C4-alkyl group; Y represents NH, N—C1–C10-alkyl, O, or S; X represents O, S, NH, N—C1–C10-alkyl, N-aryl, NSO2—C1–C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represents hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1, to R6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to a process for the preparation of zaleplon (N-[3(3-cyanopyrazolo[1,5-a]pyrim-idin-7-yl)phenyl]-N-ethyl-accramide) in the reaction of 3-dimethylamino-1-(3-N-ethyl-N-acetylamirnophenyl)-2-propen-1-one with 3-aminopyrazole-4-carbonitrile, which comprises carrying out said reaction in an aqueous solution of formic acid at formic acid concentrations in the range of 20–80% (w/w). Zaleplon is useful as an anxiolytic, a sedactive and a skeletal muscle relaxant.

Abstract: The invention provides a novel association of polyvinylpyrrolidone with chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion and a method of preparation thereof. Preferably, the weight ratio of chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion to polyvinylpyrrolidone is contained within the range from about 1:1 to about 1:200. The association can be used as a photosensitizer in photodynamic therapy and/or diagnostics or for photochemical internalization of molecules as well as a photosensitizer in cosmetology. The invention provides also a pharmaceutical composition containing the novel association, a method of treating and diagnosing diseases by a dynamic phototherapy and a method of performing cosmetic procedures with the use of the novel association as a photosensitizer.

Abstract: The invention relates to a process for the preparation of zaleplon (N-[3(3-cyanopyrazolo[1,5-a]pyrim-idin-7-yl)phenyl]-N-ethyl-accramide) in the reaction of 3-dimethylamino-1-(3-N-cthyl-N-acetylamirnophenyl)-2-propen-1-one with 3-aminopyrazole-4-carboniitrile, which comprises carrying out said reaction in an aqueous solution of formic acid at formic acid concentrations in the range of 20-80% (w/w). Zaleplon is useful as an anxiolytic, a sedactive and a skeletal muscle relaxant.